TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Benzinga Logo Benzinga By Prnewswire
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine announced 80% enrollment completion in its Phase 3 clinical trial for LPCN 1154, an oral brexanolone treatment for postpartum depression. The study is on track for topline results in Q2 2026, with 66 of 80 planned participants randomized.

Insights
LPCN   positive

Company is making steady progress in clinical trial enrollment, meeting milestones, and maintaining positive outlook on potential new treatment for postpartum depression